Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT.This article is freely available via Open Access. Click on the Publisher URL to access the full-text via the publisher's site

The Immunoexpression of Heparanase 2 in Normal Epithelium, Intraepithelial, and Invasive Squamous Neoplasia of the Cervix

Objective. Heparanase 2 (HPSE2) is expressed in various tissues, including the brain, intestine, prostate, breast, and endometrium. The aim of this study was to investigate the role of HPSE2 in cervical carcinogenesis, which has not been clarified to date.Materials and Methods. The immunoexpression of HPSE2 in normal and neoplastic cervical squamous epithelia was determined using a semiquantitative (SQ) method and an index of expression (IE) method, using Image Lab Software. A total of 230 cervical tissue samples were analyzed and segregated into the following diagnostic groups: normal (27.4%), cervical intraepithelial neoplasia 1 (CIN 1, 15.2%), CIN 2 (16.5%), CIN 3(15.2%), and invasive neoplasia (25.7%). The mean HPSE2 expression in the normal group was significantly lower than that of the other groups individually or combined (p < .001, for all combinations). The immunoexpression via the SQ method was significantly greater in the CIN 3 group compared with that in the CIN 1 group (p = .02). The mean immunoexpression of the high-grade squamous intraepithelial lesion groups was significantly greater than those of the normal and low-grade squamous intraepithelial lesion groups (p < .001) and lower compared with that of the invasive neoplasia group (p < .001). There were no statistically significant differences in the immunoexpression of HPSE2 among the different clinical states within the invasive neoplasia group.Conclusions. The SQ method produced a greater sensitivity and specificity than did the index of expression method. There was a progressive increase in the mean HPSE2 immunoexpression according to the severity of the cervical lesion from the low-grade squamous intraepithelial lesion group to the invasive neoplasm group, whereas the normal group displayed the lowest level of expression. This is a novel study concerning HPSE2 in the cervix and cervical cancer carcinogenesis.Univ Fed Sao Paulo, Dept Gynecol, Div Gynecol Oncol, Paulista Sch Med Prof, BR-04038032 Sao Paulo, BrazilUniv Taubate, Dept Obstet & Gynecol, Taubate, BrazilUniv Fed Sao Paulo, Dept Pathol, Paulista Sch Med, BR-04038032 Sao Paulo, BrazilABC, Coll Med, Dept Biochem, Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Med, Div Infect Dis, Paulista Sch Med, BR-04038032 Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Gynecol, Div Gynecol Oncol, Paulista Sch Med Prof, BR-04038032 Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Pathol, Paulista Sch Med, BR-04038032 Sao Paulo, BrazilUniv Fed Sao Paulo, Dept Med, Div Infect Dis, Paulista Sch Med, BR-04038032 Sao Paulo, BrazilWeb of Scienc

Evaluation of Hydro ThermAblator for endometrial destruction in patients with menorrhagia

Objective. To describe endometrial destruction with the Hydro ThermAblator.Design, (Canadian Task Force classification II-1).Setting. University-affiliated hospital.Patients. Twenty-six women with uncontrolled menorrhagia.Intervention. Endometrial ablation with saline heated to 90 degrees C and circulated in the uterine cavity for 10 minutes under hysteroscopic control.Measurements and Main Results. All patients tolerated the procedure well, all but one was satisfied with the results, and there were no significant side effects or complications. Seventy-seven percent of women were either amenorrheic or hypomenorrheic after 6 months, and 88% were amenorrheic or hypomenorrheic after 1 year, including one patient who was treated a second time; 87.5% were amenorrheic or hypomenorrheic at 18 months. One woman had persistent menorrhagia and was treated by hysterectomy.Conclusion. In this study, endometrial ablation was performed successfully with the Hydro ThermAblator in 25 of 26 women.Res Inst Gynecol & Oncol, Sao Paulo, BrazilColumbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USASloane Hosp Women, Div Obstet & Gynecol Pathol, New York, NY USAUniv Fed Sao Paulo, Paulista Sch Med, Sao Paulo, BrazilUniv Fed Sao Paulo, Paulista Sch Med, Sao Paulo, BrazilWeb of Scienc